Research shows that a probiotic called Saccharomyces boulardii may help reduce intestinal damage in celiac disease by activating a protective immune pathway called AhR signaling. In laboratory studies with mice, this probiotic worked together with existing gut bacteria to boost the body’s natural ability to break down tryptophan, an amino acid that calms the immune system’s overreaction to gluten. However, these are early findings in mice, and human clinical trials are needed before doctors can recommend it.
According to research reviewed by Gram, scientists discovered that a specific probiotic called Saccharomyces boulardii may help people with celiac disease by working with their gut bacteria. In lab studies with mice, this probiotic activated a protective pathway in the body that reduces gluten-related damage to the intestines. The research suggests this probiotic works by boosting the gut’s natural ability to break down certain amino acids, which helps calm the immune system’s overreaction to gluten. While these are early findings, they could lead to new treatments for people whose celiac disease doesn’t improve even after avoiding gluten.
Key Statistics
A 2026 preclinical study published in Gut Microbes found that Saccharomyces boulardii CNCM I-745 activated the AhR signaling pathway in mice with celiac disease, reducing gluten-related intestinal damage.
According to research reviewed by Gram, the probiotic enhanced gut bacteria’s capacity to break down tryptophan by up to a measurable degree when compatible bacteria like Lactobacillus reuteri were present in celiac disease patients’ microbiota samples.
A 2026 study demonstrated that Saccharomyces boulardii works synergistically with existing intestinal bacteria in celiac disease patients, targeting a previously identified microbial deficiency in tryptophan metabolism.
The Quick Take
- What they studied: Whether a specific probiotic (a type of beneficial bacteria) could help reduce intestinal damage in celiac disease by working with the gut’s natural bacteria
- Who participated: Laboratory mice genetically modified to have celiac disease, plus samples of gut bacteria from celiac disease patients
- Key finding: The probiotic Saccharomyces boulardii activated a protective immune pathway (called AhR signaling) that reduced gluten-related intestinal damage in the mice
- What it means for you: This research is early-stage and only tested in mice, but it suggests a new probiotic might eventually help celiac disease patients—especially those whose symptoms don’t improve with a gluten-free diet. More human studies are needed before doctors can recommend it
The Research Details
This was a preclinical research study, meaning scientists tested their ideas in laboratory conditions before any human trials. The researchers used mice that were genetically engineered to have celiac disease (they carried the HLA-DQ8 gene that makes people susceptible to celiac disease). They gave some mice the probiotic Saccharomyces boulardii and compared what happened to their intestines and immune systems versus mice that didn’t receive it.
The scientists also took gut bacteria samples from actual celiac disease patients and studied how the probiotic interacted with these bacteria in laboratory dishes. They looked specifically at whether the probiotic could boost a protective pathway in the body called AhR signaling, which helps calm down the immune system’s overreaction to gluten.
This type of research is important because it helps scientists understand the mechanisms—the ‘how’ and ‘why’—behind potential treatments before testing them in humans. It’s a necessary step between basic science and clinical trials.
Celiac disease affects about 1 in 100 people worldwide, and while a gluten-free diet helps most people, some patients continue having symptoms and intestinal damage even after strictly avoiding gluten (a condition called non-responsive celiac disease). Understanding the role of gut bacteria in celiac disease could unlock new treatment options for these difficult cases. This research specifically targets a known bacterial deficiency in celiac disease patients—their reduced ability to break down tryptophan (an amino acid) into compounds that activate the AhR pathway.
This study was published in a peer-reviewed scientific journal (Gut Microbes), which means other experts reviewed it before publication. However, it’s important to note this is preclinical research using mice and laboratory bacteria samples, not human trials. The findings are promising but preliminary. The study doesn’t specify the exact number of mice used or provide complete statistical details in the abstract. Before any probiotic could be recommended for celiac disease patients, human clinical trials would be necessary to confirm safety and effectiveness.
What the Results Show
The main finding was that mice with celiac disease that received the Saccharomyces boulardii probiotic showed improvement in their intestinal damage compared to mice that didn’t receive it. Specifically, the probiotic activated the AhR signaling pathway—a protective mechanism in the immune system that helps reduce the intestinal inflammation and villous atrophy (flattening of the intestinal lining) caused by gluten.
When the researchers studied how this probiotic worked, they discovered it didn’t act alone. Instead, it worked synergistically (meaning it worked better together) with bacteria already present in celiac disease patients’ guts, particularly a bacterium called Lactobacillus reuteri. The probiotic enhanced these existing bacteria’s ability to break down tryptophan, an amino acid that the body needs to activate the protective AhR pathway.
This is significant because previous research had identified that celiac disease patients have reduced levels of bacteria that can perform this tryptophan breakdown. The probiotic essentially helped restore this missing function, creating a more balanced and protective gut environment.
The research demonstrated that the specific strain tested (Saccharomyces boulardii CNCM I-745) was particularly effective at this function compared to other potential approaches. The findings also suggest that the probiotic’s benefits depend on the presence of compatible bacteria in the patient’s existing microbiota—meaning it works best when the right ‘partner’ bacteria are already present. This explains why probiotics might not work equally well for all celiac disease patients.
This research builds on earlier studies showing that gut bacteria play a role in celiac disease development and persistence. Previous research had identified that celiac disease patients have impaired tryptophan metabolism and reduced AhR pathway activation. This study is novel because it identifies a specific probiotic strain that can help restore this function and demonstrates the mechanism by which it works. While other probiotics have been tested in celiac disease, this is the first to specifically target the tryptophan-AhR pathway deficiency.
This study has several important limitations. First, it was conducted in mice and laboratory conditions, not in human patients, so results may not directly translate to people. Second, the abstract doesn’t provide complete statistical data or specify how many mice were studied. Third, the research only tested one specific probiotic strain, so we don’t know if other strains might work similarly or better. Fourth, the study didn’t test the probiotic in patients with non-responsive celiac disease (those whose symptoms persist despite a gluten-free diet), which is the population most likely to benefit. Finally, long-term safety and effectiveness in humans remain unknown and would require clinical trials.
The Bottom Line
Based on this preclinical research, Saccharomyces boulardii CNCM I-745 shows promise as a potential treatment for celiac disease, particularly for non-responsive cases. However, confidence in this recommendation is currently LOW because human clinical trials have not yet been conducted. Current medical guidance remains that a strict gluten-free diet is the primary treatment. Anyone with celiac disease should continue following their doctor’s recommendations and not self-treat with probiotics without medical supervision, as the safety and effectiveness in humans has not been established.
This research is most relevant to people with celiac disease, especially those whose symptoms don’t improve with a gluten-free diet. It’s also important for gastroenterologists and celiac disease specialists who treat these patients. The general public should be aware of this research direction but should not expect this probiotic to be available as a treatment recommendation in the near future. People with celiac disease should not start taking this specific probiotic based on this study alone.
This is very early-stage research. If human clinical trials begin soon, it would typically take 3-5 years to complete Phase 1 and Phase 2 trials (testing safety and initial effectiveness). Full approval and availability would likely take 5-10 years or longer. Realistic expectations are that this probiotic, if proven effective, would not be a standard treatment recommendation for several years at minimum.
Frequently Asked Questions
Can I take Saccharomyces boulardii if I have celiac disease?
Not yet based on clinical evidence. While a 2026 preclinical study shows promise, human trials haven’t been completed. Current research indicates this probiotic is safe, but effectiveness in celiac disease patients hasn’t been proven in humans. Consult your doctor before starting any probiotic supplement.
How does this probiotic help with celiac disease?
The probiotic activates a protective immune pathway called AhR signaling by boosting gut bacteria’s ability to break down tryptophan. This helps calm the immune system’s overreaction to gluten. However, this mechanism has only been demonstrated in mice and laboratory studies, not yet in humans.
Will this probiotic replace my gluten-free diet?
No. A gluten-free diet remains the primary treatment for celiac disease. This probiotic, if proven effective in humans, would be an additional tool—potentially helpful for people whose symptoms persist despite strict gluten avoidance. It would not replace dietary management.
When will this probiotic be available for celiac disease?
This is very early-stage research. Human clinical trials would need to be conducted first, which typically takes 3-5 years minimum. If successful, regulatory approval and availability could take several more years. Realistic timeline is 5-10+ years before potential recommendation.
Who would benefit most from this probiotic if it’s approved?
People with non-responsive celiac disease—those whose symptoms and intestinal damage persist despite strictly following a gluten-free diet—would likely benefit most. This probiotic targets the specific bacterial deficiency identified in celiac disease patients’ gut microbiota.
Want to Apply This Research?
- Users with celiac disease could track intestinal symptoms (bloating, abdominal pain, diarrhea, constipation) on a daily scale of 1-10, along with strict adherence to their gluten-free diet. This baseline tracking would be valuable if they eventually participate in clinical trials testing this probiotic.
- While this probiotic is not yet recommended, users can optimize their gut health by ensuring they’re strictly following their gluten-free diet and tracking which foods trigger symptoms. They could also discuss with their doctor whether any current probiotics might be beneficial while waiting for clinical trial results.
- For users with non-responsive celiac disease, maintain a detailed symptom diary including intestinal symptoms, energy levels, and any dietary deviations. Share this data with your gastroenterologist to help identify patterns and discuss emerging treatment options like the probiotics being studied in research.
This research is preclinical and has not been tested in human patients. The findings are promising but preliminary. Saccharomyces boulardii CNCM I-745 is not currently recommended by medical organizations for celiac disease treatment. Anyone with celiac disease should continue following their doctor’s guidance and maintain a strict gluten-free diet. Do not start taking this or any probiotic supplement without consulting your healthcare provider. This article is for educational purposes and should not be considered medical advice. Clinical trials in humans are necessary before any treatment recommendations can be made.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.